ALFA Finder| Revenue growth | Standalone +28% Q2, +21% H1; consolidated +38% Q2, +13% H1. |
|---|---|
| Margins | Gross 78%, EBITDA 35% both periods; mix-dependent; depreciation rising. |
| Demand visibility | Poultry institutional demand strong; Animal Health tender-led, lumpy. |
| Management confidence | Q1 momentum sustained into Q2; H2 similar expected. |
Growth
Consolidated revenue +38% Q2, +13% H1; consolidated PAT +44% Q2, +71% H1 (incl. one-time gain). Poultry +27% Q2, +37% H1.
Outlook
No explicit growth guidance. Sustain poultry momentum; add ruminant vaccines; possible undefined capex; 3MW solar PPA.
Risks
Animal Health H1 revenue down 14%; Nepal PPR procurement below expectations; Africa needed loan support; stricter regulatory timelines delay approvals.
Investor Presentation filed with NSE, NSE: HESTERBIO. Summary written with AI assistance from the document.
Hester Biosciences Ltd: key numbers
- Share price
- ₹2,341.30
- Market cap
- ₹1,992 Cr
- Revenue (annual)
- ₹332.6 Cr
- Net profit (annual)
- ₹55.64 Cr
- P/E (TTM)
- 14.0×Sector 43.8×
- Promoter holding
- 44.28%-9.45% QoQ
- FII holding
- 0.30%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Hester Biosciences Ltd
All →Hester Biosciences Q2 FY27 Results: Net Profit ₹20.6 Cr, Up 44.1% YoY
Hester Biosciences Ltd reported revenue from operations of ₹97.9 Cr (+37.9% YoY) and net profit of ₹20.6 Cr (+44.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹20.6 Cr · +44.1% YoY
Hester Biosciences Board Meeting Date
Hester Biosciences scheduled its Board of Directors meeting for 5 November 2026 to review unaudited H1 FY27 results. No decisions or figures are reported yet.
Hester Biosciences Management Change
Hester Biosciences disclosed Independent Director Mr. Ameetkumar Desai ceased his role on 27 October 2026 upon completing his first tenure. He opted not to seek re-appointment.
Hester Biosciences Other Announcement
Hester Biosciences reported shareholding data for the quarter ending September 2026. Two promoters were reclassified as public shareholders, reducing the promoter holding.
Hester Biosciences Capacity Expansion: ₹1.05 Cr Investment
Hester Biosciences' board approved a ₹1.05 Cr stake in SLYCE AGRI WORLD LLP for captive solar power generation. The PPA secures captive electricity supply to the company.
- Value
- ₹1.05 Cr
- Execution
- six months
Hester Biosciences Promoter Reclassification
Hester Biosciences Limited received shareholder approval to reclassify Mr. Ravin Gandhi and Ms. Bela Gandhi from the 'Promoter' category to the 'Public' category.